CARLSBAD, Calif.--(Business Wire)--
Helixis, Inc., developer of nucleic acid analysis tools, announced today that
Jay Flatley, CEO of Illumina, Inc., has joined the company`s board of directors.
Under Flatley`s leadership Illumina has become the market leader in genotyping
and next-generation sequencing systems, and has completed numerous strategic
technology acquisitions. Recognizing the company`s record of growth,
Forbesmagazinerecently named Illumina to its 2009 list of "25 Fastest-Growing
Technology Companies in the United States."
"Jay is highly respected in the life science industry and has a comprehensive
understanding of the market and customer segments that Helixis will serve with
our unique instrument platforms," said Alex Dickinson, CEO of Helixis. "In
particular he brings a strong background in operating management, which will be
invaluable as we launch our first commercial product."
Flatley`s previous experience includes senior management positions at a number
of instrument and technology companies. Prior to joining Illumina, he was
president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that
company`s initial public offering in 1993.
"I am impressed with the breadth of experience of the Helixis management team,
which includes significant accomplishments developing and commercializing real
time PCR systems and diagnostic platforms," said Flatley. "I believe that the
Helixis technologies will provide a significant new performance benchmark for
the rapidly expanding applications in genetic analysis validation."
Flatley holds a bachelor`s degree in economics from Claremont McKenna College
and bachelor`s and master`s degrees from Stanford University. He is also a
member of the board of directors for Illumina and GenVault Corporation and the
Keck Graduate Institute board of trustees.
Helixis, headquartered in Carlsbad, California, develops innovative nucleic acid
tools for research and clinical diagnostics applications. The privately held
company was founded in 2007 through a unique collaboration between molecular
biologists and engineers in the labs of Nobel Laureate David Baltimore, Ph.D.,
and Axel Scherer, Ph.D., at the California Institute of Technology. Helixis is
currently developing a new generation of high-performance, low-cost, real time
polymerase chain reaction (qPCR) systems. For more information, visit
www.helixis.com.
Dahlgren Communications
Jennifer Dahlgren, 530-265-0538
dahlgrenpr@comcast.net
or
Helixis, Inc.
Judy Macemon, 760-277-7355
judy.macemon@helixis.com
Copyright Business Wire 2009
